Boltz has raised a $110 million Series A led by Bessemer Venture Partners as the drug-design AI startup reports a 50-fold increase since June in molecular tokens processed for paying customers, its measure of model activity.

The London-based company builds software that helps pharmaceutical and biotech researchers predict how molecules bind to proteins and design candidates for laboratory testing. Boltz plans to spend the new capital on computing capacity, data and hiring.

The business earns revenue from partnerships and access to its platform and models, alongside its open-source research. Bessemer says scientists who had adopted the open models initiated all of Boltz’s partnerships to date.

The round is nearly four times the $28 million seed financing Boltz announced on January 8, when it launched Boltz Lab. Andreessen Horowitz, Amplify Partners and Zetta Venture Partners returned for the Series A, while new investors include F-Prime Capital and Benchling.

Boltz’s January agreement with Pfizer illustrates the work behind those partnerships. It calls for Boltz to adapt models using Pfizer’s historical data and build customized tools for specific drug programs. Any compounds that emerge from the work belong entirely to Pfizer.

Sources
1Boltz: Announcing our Series A ↗
2Tech.eu: London-based Boltz raises $110M Series A ↗
3Bessemer: Boltz—building towards programmable molecular design ↗
4Boltz: January launch and seed financing ↗
5Boltz and Pfizer: Strategic collaboration ↗
6Latham & Watkins: Boltz’s US$110 million Series A ↗